• Paul Ellis Marik


Hypertension is one of the most common medical disorders affecting pregnancy. It complicates 12% of pregnancies and is responsible for 18% of maternal deaths in the United States.1 The presentation of a patient with gestational hypertension may range from a mild to a life-threatening disease process. In 2000, the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy defined four categories of hypertension in pregnancy, namely2


Systemic Lupus Erythematosus Systemic Inflammatory Response Syndrome Maternal Death Magnesium Sulfate Posterior Reversible Encephalopathy Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Koonin LM, MacKay AP, Berg CJ, et al. Pregnancy-related mortality surveillance – United States, 1987–1990. Morb Mortal Wkly Rep CDC Surveill Summ. 1997;46:17–36.Google Scholar
  2. 2.
    Gifford RW, August PA, Cunningham G. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol. 2000;183:S1–S22.Google Scholar
  3. 3.
    Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol. 2004;103:981–991.PubMedCrossRefGoogle Scholar
  4. 4.
    Sibai BM, Ramadan MK, Usta I, et al. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol. 1993;169:1000–1006.PubMedGoogle Scholar
  5. 5.
    Strand S, Strand D, Seufert R, et al. Placenta-derived CD95 ligand causes liver damage in hemolysis, elevated liver enzymes, and low platelet count syndrome. Gastroenterology. 2004;126:849–858.PubMedCrossRefGoogle Scholar
  6. 6.
    Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334:494–500.PubMedCrossRefGoogle Scholar
  7. 7.
    Altman D, Carroli G, Duley L, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie trial: a randomised placebo-controlled trial. Lancet. 2002;359:1877–1890.PubMedCrossRefGoogle Scholar
  8. 8.
    Duley L, Gulmezoglu AM, Henderson-Smart DJ. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database of Syst Rev. 2003;CD000025.Google Scholar
  9. 9.
    Belfort MA, Anthony J, Saade GR, et al. A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. N Engl J Med. 2003;348:304–311.PubMedCrossRefGoogle Scholar
  10. 10.
    Sibai BM. Diagnosis, prevention, and management of eclampsia. Obstet Gynecol. 2005;105:402–410.PubMedCrossRefGoogle Scholar
  11. 11.
    Diagnosis and management of preeclampsia and eclampsia. ACOG Practice Bulletin No. 33. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2002;99:159–167.Google Scholar
  12. 12.
    Martin JN Jr, Thigpen BD, Moore RC, et al. Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. Obstet Gynecol. 2005;105:246–254.PubMedCrossRefGoogle Scholar
  13. 13.
    Cunningham FG. Severe preeclampsia and eclampsia: systolic hypertension is also important. Obstet Gynecol. 2005;105:237–238.PubMedCrossRefGoogle Scholar
  14. 14.
    Hellman LM, Pritchard JA. Williams Obstetrics. 14th ed. New York, NY: Appleton-Century-Crofts; 1971.Google Scholar
  15. 15.
    Magee LA, Cham C, Waterman EJ, et al. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. Br Med J. 2003;327:955–960.CrossRefGoogle Scholar
  16. 16.
    LaMarca BD, Ryan MJ, Gilbert JS, et al. Inflammatory cytokines in the pathophysiology of hypertension during preeclampsia. Curr Hyperten Rep. 2007;9:480–485.CrossRefGoogle Scholar
  17. 17.
    Matchaba P, Moodley J. Corticosteroids for HELLP syndrome in pregnancy. Cochrane Database of Syst Rev. 2004;CD002076.Google Scholar
  18. 18.
    Krozowski Z, MaGuire JA, Stein-Oakley AN, et al. Immunohistochemical localization of the 11 beta-hydroxysteroid dehydrogenase type II enzyme in human kidney and placenta. J Clin Endocrinol Metab. 1995;80:2203–2209.PubMedCrossRefGoogle Scholar
  19. 19.
    Blanford AT, Murphy BE. In vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by the human placenta. Am J Obstet Gynecol. 1977;127:264–267.PubMedGoogle Scholar
  20. 20.
    Forster JG, Peltonen S, Kaaja R, et al. Plasma exchange in severe postpartum HELLP syndrome. Acta Anaesthesiol Scand. 2002;46:955–958.PubMedCrossRefGoogle Scholar
  21. 21.
    Del Fante C, Perotti C, Viarengo G, et al. Daily plasma-exchange for life-threatening class I HELLP syndrome with prevalent pulmonary involvement. Transfus Apheresis Sci. 2006;34:7–9.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Division of Pulmonary and Critical Care MedicineEastern Virginia Medical SchoolNorfolkUSA

Personalised recommendations